40425_2019_679_MOESM7_ESM.tif (224.64 kB)
Additional file 7: of Safety, tolerability, pharmacokinetics, and pharmacodynamics of the afucosylated, humanized anti-EPHA2 antibody DS-8895a: a first-in-human phase I dose escalation and dose expansion study in patients with advanced solid tumors
figure
posted on 2019-08-15, 05:01 authored by Kohei Shitara, Taroh Satoh, Satoru Iwasa, Kensei Yamaguchi, Kei Muro, Yoshito Komatsu, Tomohiro Nishina, Taito Esaki, Jun Hasegawa, Yasuyuki Kakurai, Emi Kamiyama, Tomoko Nakata, Kota Nakamura, Hayato Sakaki, Ichinosuke HyodoDisposition of patients. â One patient was excluded from the efficacy analysis set because no efficacy data were available. âĄOne patient was excluded from the PK analysis set because no PK data were available. Abbreviation: PK, pharmacokinetics. (TIF 224 kb)
